CODX vs PFE

Co-Diagnostics (CODX) remains a highly speculative, high-risk investment, now facing severe financial headwinds. The company reported a significant 84.6% YoY revenue decline in FY2025 and a 60% reduction in cash, indicating rapid cash burn. Despite these challenges, CODX continues its strategic pivot, showcasing its Co-Dx PCR platform and expanding international relationships, which aligns with pr...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...